An open study of B lymphocyte depletion in systemic lupus erythematosus. - Wikidata - awgldk - TriplyDB

An open study of B lymphocyte depletion in systemic lupus erythematosus.

An open study of B lymphocyte depletion in systemic lupus erythematosus.

http://www.wikidata.org/entity/Q44183280

about

Systemic lupus erythematosus B cells as a therapeutic target in autoimmune disease SLE - Rituximab in lupus Cytokines in systemic lupus erythematosus, London, UK The Autoimmune Ecology In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.B cell depletion in autoimmune disease.Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature.Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.Hematological disorders in patients with systemic lupus erythematosus.Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.Belimumab for the treatment of systemic lupus erythematosus.Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels.Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.Immunotherapy for autoimmune and inflammatory renal diseases.Treatment of severe proliferative lupus nephritis: the current state.B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Management of refractory systemic rheumatic diseases.The discovery and development of belimumab: the anti-BLyS-lupus connection Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.Targeting B cells for the treatment of rheumatoid arthritis Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells.Cell therapy for autoimmune diseases Lupus nephritis: a review of the current pharmacological treatments.Prospects for B-cell-targeted therapy in autoimmune disease.B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.Challenges in bringing the bench to bedside in drug development for SLE.

P2860

Q24543555-C0553217-110B-4EE3-B9B1-E50D77717192 Q24804504-422B7E12-AED7-4BF5-9849-4AD36B18947D Q24804739-FE24438F-4C67-4ED9-8548-BCCA0ACF4E0E Q24804899-C21DCD5D-A25C-4853-B62B-548DAF6BEB4B Q26747427-FBE58956-6453-41CE-9A0C-8EF1DF6C4E65 Q28752150-FCFBDCF3-604B-4C47-9A40-D7E973FEAE90 Q30388433-5C79E67C-DA07-48C1-A110-E2F55B9049AB Q33360255-B0085FDF-3BBD-47B4-855E-152DBF9C0B2F Q33361142-8004F7D6-1501-4426-84C2-00F8794B0E59 Q33367691-6EFCE27F-D977-4817-8050-4B0D1333E66F Q33387348-A96BED5D-4F84-45A6-9851-BFE2A7957AD2 Q33401100-B384BC3C-E667-4F0E-8B60-3E945E3C3704 Q33411323-A0FA5F79-7628-4485-81A5-8C51BA325C6A Q34063315-6A1CC217-FB9C-4886-99AF-526A5D154A38 Q34085036-B7B1E7E5-9B30-45BC-8A9D-7495E64728A9 Q34369159-66A2BA32-3374-4890-9175-33E466CD25EB Q34455827-7322F851-F09B-4922-8620-A68BC60A88BA Q34672043-5FB70BDA-7649-4850-A109-7EF32F81181A Q34781487-72DD898F-3854-467B-B943-8DDF2998D035 Q34895937-F5D3CA96-A191-4BCB-AB9F-A338BE809CE8 Q34897189-83864BC5-5BBD-425A-9ECB-D15DF8EEEC4D Q34897437-6632FBFB-7AF9-44BA-933D-175B7ECBFEEB Q35031692-5DEDE4F8-C11F-427B-80E1-2F6CB460E0BA Q35102984-2C39BCA2-BE91-44EF-B536-59EB3DCB9BAB Q35144046-3897A68D-3E08-4F8C-96CA-D5EA66CFA8B7 Q35201234-998CF807-5B07-4A2E-82DD-BF50DFB67B42 Q35553501-44D22D09-D609-4214-B3F3-944EA0CFCAD0 Q35557832-7F793D64-374B-4483-BC8D-6F9D80E390ED Q35640956-5066F158-89F8-4368-A554-FEA4ADAEE31A Q35691272-C3D1D8C6-BCEB-45CD-B8D9-32B56576E5A0 Q35760171-65068F5B-A06D-4DF5-ACE2-2AFC93E0EE2D Q35761089-E0C9D4F8-30FB-4389-BE11-303119BB2C57 Q35794365-AFE4405A-CB0F-45E4-A28E-BAB7324F9C3F Q35824478-C6DF7B77-DD4C-48EE-824A-6998C369990A Q35824525-368F9990-4DC7-4AF9-8D15-B2A8ABB6312B Q35868954-74467336-06F0-4A1A-A74F-65DA09203957 Q35925513-7F85BACB-95B2-4444-9A3A-5F9F83EAF364 Q35930307-DBBA9844-7BC1-41C1-9669-DF96C48F7B48 Q35954653-E66C2F28-3470-4674-8A60-DD6DE0997390 Q35968394-D995A172-54C5-4EDF-8FD3-4872F7784015

P2860

An open study of B lymphocyte depletion in systemic lupus erythematosus.

http://www.wikidata.org/entity/Q44183280

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

An open study of B lymphocyte depletion in systemic lupus erythematosus.

@en

An open study of B lymphocyte depletion in systemic lupus erythematosus.

@nl

type

label

An open study of B lymphocyte depletion in systemic lupus erythematosus.

@en

An open study of B lymphocyte depletion in systemic lupus erythematosus.

@nl

prefLabel

An open study of B lymphocyte depletion in systemic lupus erythematosus.

@en

An open study of B lymphocyte depletion in systemic lupus erythematosus.

@nl

P1433

Q44183280-C6E86736-E09C-4242-AEEF-EAB67F4CA494

P1476

Q44183280-923AF9D2-3C97-4C4D-87D4-C75C779A09F8

P2093

Q44183280-42977930-FEDA-458D-8143-71CCF044FE6A

Q44183280-7034B981-3494-425F-922B-F8E79CEAFE82

Q44183280-A8344727-C273-42BA-9277-C21F63F89E90

P2860

Q44183280-2F2D0E60-88DC-4349-A4AF-53692A12FC8F

Q44183280-7168D38B-EDBB-4496-937F-39A687EAFDE6

Q44183280-8753434F-C899-4D81-8CAE-13443E7FD9F6

Q44183280-AAADC80B-0C95-458F-9F66-2D61A4FBB318

Q44183280-AC3449C3-5C03-45FC-B945-DA854AEB2162

Q44183280-AE214420-2C81-4F23-9568-0465B0CFF2C5

Q44183280-B2F45CEA-C4EF-4721-B0AC-2F1ED83E90A7

Q44183280-ED4FCB66-6AF5-46B3-9E2A-9E411466DDDE

P304

Q44183280-B8FCC345-3DB1-4E74-A4F9-D84FEF87A9AB

P31

Q44183280-8F1E7B3D-7182-4531-A220-2974F83C92E4

P356

Q44183280-0238DCA0-DF73-4995-ADC2-578BA32C13D8

P433

Q44183280-B544CB99-CF7B-4216-94A0-724836AE6BAE

P478

Q44183280-1DF67F06-224A-4E23-96C0-D7C1BADD2299

P50

Q44183280-1FADC50F-81F2-4491-A405-F1B65BE250CE

Q44183280-E15EF368-C1B4-47B4-914B-209CDE4D29C1

P577

Q44183280-73B84B7C-6359-48AB-B298-89D1C86267F4

P5875

Q44183280-06B6DCC9-57D0-46FD-8731-2F7B84B9791E

P698

Q44183280-204EA5F6-CCA1-4D75-986B-B2F2B05383BF

P356

P1433

Arthritis & Rheumatology

P1476

An open study of B lymphocyte depletion in systemic lupus erythematosus.

@en

P2093

Geraldine Cambridge

http://www.w3.org/2001/XMLSchema#string

Jonathan C Edwards

http://www.w3.org/2001/XMLSchema#string

Maria J Leandro

http://www.w3.org/2001/XMLSchema#string

P2860

Do self-perpetuating B lymphocytes drive human autoimmune disease?

The 1982 revised criteria for the classification of systemic lupus erythematosus

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

Clinical applications of anti-CD20 antibodies.

The role of antibodies to DNA in systemic lupus erythematosus--a review and introduction to an international workshop on DNA antibodies held in London, May 1996.

["Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab].

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

P304

2673-2677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.10541

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

David A. Isenberg

Michael R Ehrenstein

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11076198

http://www.w3.org/2001/XMLSchema#string

P698

12384926

http://www.w3.org/2001/XMLSchema#string